Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Antibody Drug Conjugate Market

ID: MRFR/Pharma/14416-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026

US Antibody Drug Conjugate Market Research Report: Size, Share, Trend Analysis By Types (Cytotoxic Drug Conjugates, Immunomodulatory Drug Conjugates, Radiolabeled Drug Conjugates, Dual Action Drug Conjugates), By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Disorders), By Mechanism of Action (Targeted Delivery, Cell Cycle Disruption, Immune Modulation, Antibody-Dependent Cellular Cytotoxicity) and By Route of Administration (Intravenous, Subcutaneous, Intramuscular) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Antibody Drug Conjugate Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Security, Access Control and Robotics, BY Type (USD Million)
  49.     4.1.1 Cytotoxic Drug Conjugates
  50.     4.1.2 Immunomodulatory Drug Conjugates
  51.     4.1.3 Radiolabeled Drug Conjugates
  52.     4.1.4 Dual Action Drug Conjugates
  53.   4.2 Security, Access Control and Robotics, BY Therapeutic Area (USD Million)
  54.     4.2.1 Oncology
  55.     4.2.2 Autoimmune Diseases
  56.     4.2.3 Infectious Diseases
  57.     4.2.4 Neurological Disorders
  58.   4.3 Security, Access Control and Robotics, BY Mechanism of Action (USD Million)
  59.     4.3.1 Targeted Delivery
  60.     4.3.2 Cell Cycle Disruption
  61.     4.3.3 Immune Modulation
  62.     4.3.4 Antibody-Dependent Cellular Cytotoxicity
  63.   4.4 Security, Access Control and Robotics, BY Route of Administration (USD Million)
  64.     4.4.1 Intravenous
  65.     4.4.2 Subcutaneous
  66.     4.4.3 Intramuscular
  67. 5 SECTION V: COMPETITIVE ANALYSIS
  68.   5.1 Competitive Landscape
  69.     5.1.1 Overview
  70.     5.1.2 Competitive Analysis
  71.     5.1.3 Market share Analysis
  72.     5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  73.     5.1.5 Competitive Benchmarking
  74.     5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  75.     5.1.7 Key developments and growth strategies
  76.       5.1.7.1 New Product Launch/Service Deployment
  77.       5.1.7.2 Merger & Acquisitions
  78.       5.1.7.3 Joint Ventures
  79.     5.1.8 Major Players Financial Matrix
  80.       5.1.8.1 Sales and Operating Income
  81.       5.1.8.2 Major Players R&D Expenditure. 2023
  82.   5.2 Company Profiles
  83.     5.2.1 Roche (CH)
  84.       5.2.1.1 Financial Overview
  85.       5.2.1.2 Products Offered
  86.       5.2.1.3 Key Developments
  87.       5.2.1.4 SWOT Analysis
  88.       5.2.1.5 Key Strategies
  89.     5.2.2 Pfizer (US)
  90.       5.2.2.1 Financial Overview
  91.       5.2.2.2 Products Offered
  92.       5.2.2.3 Key Developments
  93.       5.2.2.4 SWOT Analysis
  94.       5.2.2.5 Key Strategies
  95.     5.2.3 AstraZeneca (GB)
  96.       5.2.3.1 Financial Overview
  97.       5.2.3.2 Products Offered
  98.       5.2.3.3 Key Developments
  99.       5.2.3.4 SWOT Analysis
  100.       5.2.3.5 Key Strategies
  101.     5.2.4 Gilead Sciences (US)
  102.       5.2.4.1 Financial Overview
  103.       5.2.4.2 Products Offered
  104.       5.2.4.3 Key Developments
  105.       5.2.4.4 SWOT Analysis
  106.       5.2.4.5 Key Strategies
  107.     5.2.5 Bristol-Myers Squibb (US)
  108.       5.2.5.1 Financial Overview
  109.       5.2.5.2 Products Offered
  110.       5.2.5.3 Key Developments
  111.       5.2.5.4 SWOT Analysis
  112.       5.2.5.5 Key Strategies
  113.     5.2.6 Novartis (CH)
  114.       5.2.6.1 Financial Overview
  115.       5.2.6.2 Products Offered
  116.       5.2.6.3 Key Developments
  117.       5.2.6.4 SWOT Analysis
  118.       5.2.6.5 Key Strategies
  119.     5.2.7 Seattle Genetics (US)
  120.       5.2.7.1 Financial Overview
  121.       5.2.7.2 Products Offered
  122.       5.2.7.3 Key Developments
  123.       5.2.7.4 SWOT Analysis
  124.       5.2.7.5 Key Strategies
  125.     5.2.8 Merck & Co. (US)
  126.       5.2.8.1 Financial Overview
  127.       5.2.8.2 Products Offered
  128.       5.2.8.3 Key Developments
  129.       5.2.8.4 SWOT Analysis
  130.       5.2.8.5 Key Strategies
  131.     5.2.9 Takeda Pharmaceutical (JP)
  132.       5.2.9.1 Financial Overview
  133.       5.2.9.2 Products Offered
  134.       5.2.9.3 Key Developments
  135.       5.2.9.4 SWOT Analysis
  136.       5.2.9.5 Key Strategies
  137.   5.3 Appendix
  138.     5.3.1 References
  139.     5.3.2 Related Reports
  140. 6 LIST OF FIGURES
  141.   6.1 MARKET SYNOPSIS
  142.   6.2 US MARKET ANALYSIS BY TYPE
  143.   6.3 US MARKET ANALYSIS BY THERAPEUTIC AREA
  144.   6.4 US MARKET ANALYSIS BY MECHANISM OF ACTION
  145.   6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  146.   6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
  147.   6.7 RESEARCH PROCESS OF MRFR
  148.   6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
  149.   6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
  150.   6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
  151.   6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
  152.   6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 (% SHARE)
  153.   6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 TO 2035 (USD Million)
  154.   6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY THERAPEUTIC AREA, 2024 (% SHARE)
  155.   6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
  156.   6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY MECHANISM OF ACTION, 2024 (% SHARE)
  157.   6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY MECHANISM OF ACTION, 2024 TO 2035 (USD Million)
  158.   6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  159.   6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
  160.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  161. 7 LIST OF TABLES
  162.   7.1 LIST OF ASSUMPTIONS
  163.     7.1.1
  164.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  165.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  166.     7.2.2 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
  167.     7.2.3 BY MECHANISM OF ACTION, 2025-2035 (USD Million)
  168.     7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  169.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  170.     7.3.1
  171.   7.4 ACQUISITION/PARTNERSHIP
  172.     7.4.1

US Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Type (USD Million, 2025-2035)

  • Cytotoxic Drug Conjugates
  • Immunomodulatory Drug Conjugates
  • Radiolabeled Drug Conjugates
  • Dual Action Drug Conjugates

Security, Access Control and Robotics By Therapeutic Area (USD Million, 2025-2035)

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Neurological Disorders

Security, Access Control and Robotics By Mechanism of Action (USD Million, 2025-2035)

  • Targeted Delivery
  • Cell Cycle Disruption
  • Immune Modulation
  • Antibody-Dependent Cellular Cytotoxicity

Security, Access Control and Robotics By Route of Administration (USD Million, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Intramuscular

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓